

---

# ISPOR List of Presentations

---

## ISPOR 22<sup>nd</sup> Annual European Congress, November 2019, Copenhagen, Spain

### IP2

Is Delayed Access Due to Issues of HTA Capacity a Necessary Reality or an Unacceptable Problem?

*Griffiths M, Low E, Drummond M, Tilson L*

### IP12

A Formal System for Using Real-World Evidence to Revisit the HTA Decision: More Trouble Than It's Worth?

*Brooks-Rooney C, Towse A, Kusel J, Halliday A*

### PBI44

Real-World Evidence in Gene Therapies: Recommendations Versus Reality

*Allen G, Warnants E, Summers D, Evans J*

### PCN20

Accurate Predictions of Life Year Gains for Immuno-Oncology Therapies in the Long Term? An Analysis Based on Published Checkmate 057 Nivolumab Data

*A. Porteous,1 K. Herbert,2 C. Painter1*

### PCN336

Parallel Scientific Advice from NICE and CADTH: Would One Submission Fit All?

*S. Gibson, M. Atkinson, R. Beale, R. Wickstead, M. Griffiths*

### PDG85

Trust the Experts? Acceptance of Expert Elicitation in the National Institute for Health and Care Excellence (NICE) Single Technology Appraisal (STA) Process

*van Hest N, Upton E, Ader J, Woodhouse F, O'Connor M-E*

### PNS42

To What Extent Does Seeking Clinical Expert Opinion for Model Inputs Reduce the Cost of Uncertainty? A Conceptual Approach Using Expected Value of Perfect Parameter Information (EVPPPI)

*van Hest N, Griffiths M, Hearmon N*

### PNS413

Development, Validation and Concordance of Clinical Code Sets Used in Real-World Database Studies

*A. Artignan, A. Bobrowska, L. Ashworth, M. Murton, M. Zemyarska, A. Buchanan-Hughes*

### PNS209

Impact of Generics and Biosimilars on Branded Drug Listing Decisions in Singapore

*S. Lim, V. Koh, M. Yoshino, C. Brooks-Rooney*

### PRO156

Approaches to the Collection of Utility Values for Rare Diseases

*Bewicke-Copley H, Evans J, Newell I, Pritchett D, Ruban-Fell B, Griffiths A*

---

## ISPOR 24<sup>th</sup> Annual International Meeting, May 2019, New Orleans, USA

### IP26

Could Formal HTA Be The Solution To High Healthcare Costs In The USA?

*Ghosh W, Ollendorf DA, Butt T, Breen S*

### PIN46

Vax-The-Nation: A Budget Impact Analysis of Costs Associated with Measles Outbreaks in the USA Through Increasing Measles, Mumps and Rubella Vaccination Uptake

*Painter C, Curteis T, Walker E, Hearmon N*

### PMH40

Expansion of State Medicaid Programs: Increased Patient Access to Opioid Replacement Therapy?

*Atrah S, O'Leary C, Forrest R, Beale R*

### PMU90

Framework Synthesis (FS) of Qualitative and Quantitative Evidence to Explore the Differential Diagnosis (DDx) of Diarrhea in Neuroendocrine Tumor (NET) Patients

*Worthington E, Murton M, Khan M, Walter T, Grande E, Buchanan-Hughes A*

#### **PNS49**

What's Trending? Pharmacoeconomic Publications in the US between 2009–2018

*van Hest N, Ashworth L, Wickstead R*

#### **PNS114**

Bundled Payments for Care Improvement Advanced (BPCI-A): An Analysis of Public Communications During the Application Period

*Clausen K, Phillips E, Wickstead R, Chambers H*

#### **PNS117**

Patient, Payer and Manufacturer Perspectives on Four Cost-Control Mechanisms for Pharmaceuticals

*Evans J, Haskins-Coulter T, Griffiths M, Beale R*

#### **PNS174**

Influencing ICER: A Review of Manufacturer Involvement in ICER Assessments

*Atkinson M, Allen G, Morten P*

#### **PNS182**

Real-World Evidence on the Rise: Evaluating the Use of Real-World Evidence in ICER Assessments of Comparative Clinical Effectiveness

*Drane E, Upton E, Morten P*

---

### **ISPOR 21<sup>st</sup> Annual European Congress, November 2018, Barcelona, Spain**

#### **MD1**

Evidence Development Timeline of Medical Devices in the UK: Where do MedTech Innovation Briefings Fit?

*Overhill A, Chen G, Upton E, Peirce V, Marsh W*

#### **PMD167**

Health Technology Assessment of mHealth Applications: Slow Progress in a Fast-Paced Industry?

*Ridley CJA, Tomlinson P, Marsh W*

#### **PMS66**

Improving Patient and Financial Outcomes in the NHS: Early Arthritis Service Increases Patient Satisfaction Whilst Saving Costs

*Nisar M, Tomlinson P, Taylor C, Beale R*

#### **PMD134**

Medical Device Appraisal in the UK: What Are the Common Pitfalls of Manufacturer Literature Reviews?

*Macnair P, Marsh W*

#### **PMD135**

Determining Factors for Decision-Making in the Medical Technologies Evaluation Programme

*Peirce V, Atkinson M, Marsh W*

#### **PRM109**

Exploring the Use and Acceptance of Alternative Survival Modelling Approaches for Immuno-Oncology Therapies in UK Technology Assessments

*Porteous A, van Hest N, Griffiths M, Morten P*

---

### **ISPOR 20<sup>th</sup> Annual European Congress, November 2017, Glasgow, United Kingdom**

#### **IP9**

Should Rare Oncology Treatments be Considered True Orphans?

*Griffiths A, Gajraj E, Pantziarka P, Cattaneo I*

#### **MD4**

Evaluating Matching-Adjusted Indirect Comparison and Simulated Treatment Comparison Techniques: Impact on Health-Related Quality of Life of Focussed Ultrasound Thalamotomy and Other Interventions for the Treatment of Medication-Refractory Essential Tremor

*Langford BE, Ridley CJ, Beale RC, Marsh W, Caseby SC, Richard L*

#### **SY4**

Do EU5 Countries with Favourable Healthcare Expenditure and Reimbursement Indicators have Better Patient Reported Access to Treatments for Rare Diseases?

*Allen G, Hall A, Hanman K, Le Fevre R, Griffiths A*

#### **PCN201**

No EQ-5D? Analysis of Alternative Utility Value Sources used in NICE Appraisals for Oncology Indications

*Beale RC, Wickstead RM, Chen G, Walker E, Griffiths M*

### PHP3

Consumer Comments in Health Technology Assessment in Australia: How Common and Influential are They?

*Viswambaram A, McManus K, Miah R, Miles G*

### PHP60

Health Technology Assessment in Singapore: Shining a Light in the Darkness

*Viswambaram A, Brooks-Rooney C*

### PHP241

How do NICE Evidence Review Groups Perceive Single Technology Appraisals Presenting Limited Evidence of Comparative Treatment Efficacy?

*Langford BE, Beaver S, Besford M, Castell A, Dierker Viik A, Eddowes LA*

### PHP247

When the Price is Right: When, in Practice, are Confidential Discounts Introduced in the NICE Process?

*Noon K, Ulrich A, Painter C, Montgomery S*

### PHP262

An Audit of Evidence Review Group Criticisms of Systematic Literature Reviews Conducted to Inform Manufacturers' Submissions to the National Institute for Health and Care Excellence

*Leonard S, Summers J, Young E*

### PHP300

Payers, Politics And Pandemonium: An Insight Into the Future UK Pricing and Market Access Environment

*Spoors J, Kusel J*

### PMD156

Does the NICE Diagnostics Assessment Programme Use an Empirical ICER Threshold?

*Chen G, Koczula KM, Peirce VJ, Marsh W*

### PRM118

Model Types Submitted to NICE: What is Considered Appropriate by Evidence Review Groups?

*Hearmon NC, Ghosh W, Buguth B, Kusel J*

### PRM242

An Exploration of the Methodology of Published Systematic Literature Reviews on "Burden of Disease"

*Buchanan-Hughes AM, Beaver S, Fell B, Summers J, Young E*

### PSY148

Why do 'True' Orphan Medicines Have Such a Low Acceptance Rate When Assessed by the SMC?

*Morten P, Ulrich A, Le Fevre R, Eddowes LA*

---

## ISPOR 22<sup>nd</sup> Annual International Meeting, May 2017, Boston, USA

### PHP266

Value Frameworks to Set Tongues Wagging: Analysis of Opinions and Discussions on Key Value Frameworks

*Koczula K, Noon K, Wickstead R, Ghosh W, Uchea C, Kusel J*

### PHS131

Inequity in Healthcare Access in Asian Countries with Reportedly High Universal Health Coverage Levels

*Evans J, Ma C, Noon K, Steeves S*

### PMD74

Cost-Effectiveness of PET-CT Versus Adrenal Vein Sampling for the Diagnosis of Hypertension Caused by Primary Aldosteronism

*Lin Z, Kusel J, Ghosh W, Brown M*

### PMD118

Small and Medium-Sized Enterprises: How Do They Fare in the UK Medical Technologies Evaluation Programme (MTEP)?

*Ridley C, Marsh W*

---

## ISPOR 19<sup>th</sup> Annual European Congress, November 2016, Vienna, Austria

### IP7

How Should Biosimilars be Valued and Should They Undergo Health Technology Assessment?

*Kusel J, Psachoulia E, McKenna F, Walker A*

### IP21

Is Off-Label Drug Use Enhancing or Limiting Access for Patients with Rare Diseases?

*Griffiths A, Scannell J, Timmis O, Pinilla-Dominguez P*

### **PRM128**

Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: An Exploratory Evaluation Using Advanced Hierarchical Network Meta-Analysis Techniques  
*Langford B, Wickstead R, Murphy D, Marsh W, Beale R, Evans J, Kusel J, Griffiths M*

### **PRM210**

Adapting to the Challenge: How are Innovative Study Designs Being Used in Rare Diseases?  
*Berry L, Eddowes L*

### **PIN70**

Health State Utility Values Measured Using the EuroQol 5-Dimensions Questionnaire in Adults with Chronic Hepatitis C: A Systematic Literature Review  
*Buchanan-Hughes A, Hanman K, Langford B, Eddowes L*

### **PHP6**

Patient Group Submissions in Health Technology Assessment in Scotland: Prevalence and Impact  
*Hamilton K, Hanman K, Griffiths M*

### **PHP94**

Do Scottish Formulary Decisions Match Recommendations Made by the SMC?  
*Beale R, Kusel J*

### **PCV16**

Pharmacological Interventions for Familial Hypercholesterolaemia in Children and Adolescents: A Systematic Literature Review  
*Wickstead R, Evans J, Langford B, Beale R, Marsh W, Kusel J, Griffiths M*

### **PSY156**

A Value for Money Threshold for New Technologies for Very Rare Conditions: Does the NICE Highly Specialised Technology Committee Employ One?  
*Kusel J, Griffiths A, Spoors J*

### **PCN236**

Innovative Therapies for the Treatment of Cancer: An Overview of Late-Phase Clinical Development  
*Resemann H, Chainani N, Morten P, Griffiths M*

### **PCN294**

Reconsidering Drugs Funded via the Cancer Drugs Fund in England: What's New This Time?  
*Morten P, Lin Z, Kusel J*

### **PMD23**

Cost of Ebola Virus Disease Diagnosis Using Rapid Point-of-Care Diagnostics in Sierra Leone  
*Evans J, Hearmon N, Beale R, Marsh W*

### **PMD59**

Investigating the Cost-Effectiveness of Genetic Counselling for Couples at Known Risk of Having Children with Tay-Sachs Disease: A Two-Generation Model  
*Ghosh W, Griffiths M, Griffiths A*

---

## **ISPOR 7<sup>th</sup> Asia-Pacific Conference, September 2016, Singapore**

### **IP3**

Joint HTA: The Next Step for the ASEAN Economic Community?  
*Chen G, Ngorsurachet S, Redekop K*

### **IP15**

Should Productivity Losses due to Illness be Considered in Health Economic Evaluations?  
*Brooks-Rooney C, Redekop K, Wee HL, Milea D*

### **PCV33**

Measurement of Adherence to Anti-Hypertensive Drugs in Asia  
*Ma Q, Kao C, Miles G, Chen G*

### **PCV54**

Quantifying Informal versus Formal Care, and Financial Caregiver Burden, for Stroke Patients in Asia: A Structured Literature Review  
*Wayman S, Langford B, Buchanan-Hughes A, Chen G*

### **PHP38**

Universal Health Coverage in Countries across East and South East Asia – Associations between Health Expenditure and Service Provision  
*Evans J, Wickstead R, Hanman K, Steeves S*

### **PIN15**

Economic Burden of Antibiotic-resistant Nosocomial Gram-Negative Bacteraemia in Singapore Hospitals  
*Chen G, Lim S, Ma Q, Kao C, Ghosh W*

### **PMH16**

Estimating the Economic Impact due to Productivity Losses of Diabetes and Major Depressive Disorder in Singapore: Human Capital versus Friction Cost Approaches  
*Brooks-Rooney C, Griffiths M, Chen G*

---

## **ISPOR 21<sup>st</sup> Annual International Meeting, May 2016, Washington DC, USA**

### **PHP54**

The Trade-Off Between QALY Maximisation and Social Values: A Systematic Review of Public Opinion Surveys  
*Buchanan-Hughes A, Kusel J*

---

## **ISPOR 18<sup>th</sup> Annual European Congress, November 2015, Milan, Italy**

### **PCN323**

Does Budget Impact Affect Reimbursement Decisions Made by the Cancer Drugs Fund in England?  
*Stewart G, Kusel J, Montgomery S*

### **PUK15**

Investigating the Cost-Effectiveness of Bacterial Whole-Genome Sequencing for Enabling Targeted Antibiotic Selection in Urinary Tract Infections  
*Buchanan-Hughes A, Griffiths A, Evans J, Slater D, Eddowes L*

### **PDB116**

The Role of Education in the Management of Type 1 Diabetes Mellitus in England  
*Toth C, Marsh W, Stewart G, Yang L, Bridges H, Kusel J*

### **PRM237**

Using Incentives to Improve Health-Related Behaviours: A Review of Incentive-Based Trials  
*Bunting C, Lim S, Morten P*

### **PRM267**

Development of a PRECIS-2 Scoring Grid: How Pragmatic are Pragmatic Trials of Surgical and Pharmaceutical Interventions?  
*Chen G, Ma Q, Yang L, Ghosh W, Kusel J*

### **PRM55**

Hunting for Randomised Controlled Trials (RCTs): A Comparison of Search Filters Designed to Identify RCTs  
*Steeves S, Buchanan-Hughes A, Evans J, Leonard S*

---

## **ISPOR 5<sup>th</sup> Latin America Conference, September 2015, Santiago, Chile**

### **IP2**

Disinvestment in Latin America: What are the Experiences, Challenges and Proposals for its Successful Implementation?  
*Agirrezabal I, Rodríguez A, Esandi ME, Gutiérrez-Ibarluzea I*

### **PP4**

An Undeveloped Picture: The Availability of Utility Valuations in Latin America. How Will They Affect QALYs?  
*Montgomery S, Stewart G, Kusel J*

### **PHP23**

Pharmaceutical Cost-Containment Strategies – Opinions of the Pharmaceutical Industry and HTA Bodies in Latin America  
*Beale R, Stewart G, Agirrezabal I, Kusel J*

### **PHP24**

Immunisation in Latin America: Factors Preventing Uptake of Cost-Effective Vaccines  
*Burgon J, Bunting C, Eddowes LA, Wilson T*

### **PHP38**

Considerations for the Adoption of the WHO-CHOICE Cost-Effectiveness Threshold in Latin America  
*Griffiths M, Latchford J, Stewart G, Kusel J*

### **PHP40**

Clinical Trial Trends in Latin America: Communicable Versus Non-Communicable Disease  
*Anderson R, Wilson T*

### **PHP54**

Disinvestment Initiatives in Latin America: A Systematic Literature Review  
*Agirrezabal I, Latchford J, Gutierrez-Ibarluzea I*

### **PRM9**

A Systematic Review of Economic Evaluations in Latin America: Assessing the Factors That Affect Adaptation and Transferability of Results

*Stewart G, Slater D, Maruszczak M*

---

## **ISPOR 20<sup>th</sup> Annual International Meeting, May 2015, Philadelphia, USA**

### **PMD34**

A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Detecting and Monitoring Outbreaks of MRSA

*Agirrezabal I, Buchanan-Hughes A, Eddowes L, Luheshi L, Sagoo GS, Török ME*

### **PMD37**

A System Dynamics Model for the Cost-effectiveness Evaluation of Bacterial Whole-genome Sequencing for Monitoring Outbreaks of *Clostridium difficile*

*Buchanan-Hughes A, Agirrezabal I, Eddowes L, Luheshi L, Török ME, Sagoo GS*

### **PRM28**

Implication of the Inter-relatedness of the Proportional and Absolute QALY Shortfall Measurements for Disease Burden

*Kusel J, Beale R, Maruszczak M*

### **PHP107**

The WHO-Choice Cost-effectiveness Threshold: A Country-level Analysis of Changes Over Time

*Griffiths M, Maruszczak M, Kusel J*

---

## **ISPOR 17<sup>th</sup> Annual European Congress, November 2014, Amsterdam, The Netherlands**

### **W5**

Value-based Assessment for NICE: How to Do the Calculations

*Kusel J, Boysen M, Hatswell AJ, Shah K*

### **HS3**

Impact of Morbidity in Populations of North London Clinical Commissioning Groups on Patient Admission Rates and GP Referrals

*Groom ZC, Burgon J, Eddowes LA, Wilson T, Kusel J*

### **QA1**

Economic Orphans? The Prevalence of Child-specific Utilities in NICE Appraisals for Paediatric Indications

*Montgomery S, Hassan M, Kusel J*

### **NI2**

Predicting the Impact of Value-based Assessment on Future NICE Appraisals

*Beale RC, Maruszczak M, Kusel J*

### **PGI17**

A Cost of Care Model for Inflammatory Bowel Disease with a UK NHS Perspective

*Miles G, Leonard SA, Ghosh N, Premchand P*

### **PND49**

Expected Value of Partial Perfect Information for the Disability Progression Efficacy of Teriflunomide and Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis

*Maruszczak M, Kusel J, Adlard N*

### **PMH63**

Antidepressant Use and Suicide Rate in England: The Geographic Divide

*Anderson R, Wilson T, Griffiths M*

### **PRM124**

Discrete Event Simulation for the Cost-effectiveness Evaluation of PET-CT Scans in the Diagnosis of Conn's Disease in Hypertensive Patients

*Maruszczak M, Stewart G, Kusel J, Brown MJ*

### **PRM28**

Systematic Review and Critique of Health Economic Models of Relapsing-remitting Multiple Sclerosis in the UK

*Kusel J, Maruszczak M, Montgomery S, Allen F, Adlard N*

### **PCN260**

Investigating the Use of Personalised Medicine in Cancer Trials – An Update

*Hamilton K, Wilson T*

---

## ISPOR 6<sup>th</sup> Asia-Pacific Conference, September 2014, Beijing, China

### IP2

Disinvestment in Asia-Pacific: How Can This Be Implemented in HTA and What Can Be Learnt from Europe?

*Brooks-Rooney C, Kamae I, Tan ST, Gutiérrez-Ibarluzea I*

### QA2

An Analysis of New Health Technologies and Reimbursement Pricing Structure in Taiwan

*Stewart G, Brooks-Rooney C*

### PCN13

Analysing the Effects of a Disinvestment Decision in Breast Cancer Screening Programmes in Asia-Pacific Countries: A Modelling Approach

*Agirrezabal I, Bunting C, Brooks-Rooney C*

### PCN39

The Differences Between Cancer Drug Approvals in Japan and the USA

*Anderson R, Brooks-Rooney C*

### PDB9

Impact of Ethnicity on the Efficacy and Safety Outcomes of Anti-Diabetes Drugs – Case Study of Liraglutide in Asian and Non-Asian Populations

*Chen G, Yang L, Lantaff B, Kusel J, Warnakula S, Brooks-Rooney C*

### PMS30

Closing the Gap: Reduced Delay to Drug Marketing Approval Between the West and Asia

*Hamilton KI, Eddowes LA, Brooks-Rooney C*

### PIN33

The Differences Between Infectious & Parasitic Drug Approvals in Japan and the USA

*Anderson R, Brooks-Rooney C*

---

## ISPOR 19<sup>th</sup> Annual International Meeting, May 2014, Montreal, Canada

### HC2

The Impact of NICE's End-Of-Life Threshold on the Availability of New Cancer Therapies in England and Wales

*Stewart G, Eddowes L, Hamerslag L, Kusel J*

### PHP27

An Update on How NICE Manage Off-Label Comparators

*Kusel J, Steeves S, Maruszczak M, Pettit L, Wilson T, Taylor D*

### PGI30

Patterns of Generic and Proprietary Prescribing of Proton Pump Inhibitors (PPIs) Over Time in England

*Hamilton K, Kusel J, Leonard S*

### PDB128

Insulin Pumps for the Treatment of Type 1 Diabetes Mellitus: Why is Uptake so Low in the UK?

*Marsh W, Wilson T, Kusel J*

---

## ISPOR 16<sup>th</sup> Annual European Congress, November 2013, Dublin, Ireland

### IP13

Should Off-Label Agents Be Used as Comparators in Health Technology Assessments?

*Kusel J, Walker W, Spackman E, Andersson C*

### PCN207

Impact of Recommended Pharmaceuticals on Cancer Mortality: Analysis of Real-Life Data

*Wilson T, Hamerslag L, Kusel J*

### PHP152

The Relationship Between Scientific Research, Clinical Trials and FDA Drug Approval

*Burgon J, Hamerslag L*

### PHP166

How Does the Uncertainty Around the Expected ICER Affect NICE Decisions?

*Barber R, Steeves S, Wilson T, Hamerslag L, Kusel J*

### PMH68

How Well Do We Understand the Economic Burden Associated with Dementia? A Focus on Trends in Care Home Costs and Future Perspectives in the UK

*Griffiths M, Hamerslag L, Wilson T, Stewart G, Kusel J*

### PMS27

Global Variations in Biologics Access and Rheumatoid Arthritis Treatment Costs

*Miles G, Bell J, Wilson T, Hamerslag L, Kusel J*

---

## ISPOR 18<sup>th</sup> Annual International Meeting, May 2013, New Orleans, USA

### PSY89

Treatment Options in Obesity: Is Clinical Development Keeping up with an Expanding Population?

*Hay J, Barber R, Kusel J, Wilson T*

### PMS48

Quality of Life in Rheumatoid Arthritis: How Much Do We Really Know?

*Miles GA, Rolfe F, Kusel J, Brooks-Rooney C, Hay J*

### PHP104

Assessing the Implementation of NICE Guidance: Is There a Correlation Between Recommendations and Uptake in Clinical Practice

*Pettit L, Leonard S, Brooks-Rooney C, Hamerslag L, Kusel J*

---

## ISPOR 15<sup>th</sup> Annual European Congress, November 2012, Berlin, Germany

### NI2

The Use of Off-Label Comparators in NICE Appraisals – An Indirect Endorsement?

*Kusel J, Wong GK, Hay JA, Pettit LJ*

### CA2

Applying a Value-Based Price Across Different Disease Areas

*Wilson TJ, Kusel J, Brooks-Rooney C, Costello S*

### PCN144

Access to Cancer Interventions Across the UK: To What Extent Does SMC Advice Agree with NICE's End-of-Life Therapies?

*Hamerslag L, Brooks-Rooney C, Zhou A, Pettit L*

---

## ISPOR 5<sup>th</sup> Asia-Pacific Conference, September 2012, Taipei, Taiwan

### HC4

Tapping into the Asian Pharmaceutical Market: Global Firms Go Local?

*Wong GKW, Brooks-Rooney C, Hamerslag L, Timm B, Wilson TJ, Costello S*

### PHP82

The Characteristics of Clinical Trials in Asia  
*Brooks-Rooney C, Wong GKW, Hamerslag L, Costello S*

### PRM11

The Use of Biomarkers in Cancer Trials in Asia  
*Hamerslag L, Wilson T, Brooks-Rooney C*

---

## ISPOR 17<sup>th</sup> Annual International Meeting, June 2012, Washington DC, USA

### PCN148

The Use of Personalised Medicine in Cancer Trials  
*Wilson TJ, Hamerslag L, Kusel J, Brooks-Rooney C, Rolfe F, Costello S*

### PHP66

Assessing Agreement Between Patient Access Schemes: Review of NICE and SMC Guidance  
*Timm B, Leonard S, Haynes S*

### PRM11

The Rise of Budget Impact Analyses – Another Hurdle in the Health Technology Approval Process?  
*Wong GKW, Hamer N, Wilson T, Costello S*

---

## ISPOR 14<sup>th</sup> Annual European Congress, November 2011, Madrid, Spain

### RS2

Cost-effectiveness of End-of-life, Life-extending Interventions: NICE's Cost-effectiveness Threshold Explored

*Hamerslag L, Haynes S, Kusel J, Costello S*

### RS4

The Interim Cancer Drugs Fund – How To Not Spend £50 Million

*Timm B, Brooks-Rooney C, Hamerslag L, Costello S*

### PHP123

To What Extent Does Advice From the SMC Agree with that Published by NICE?

*Leonard SA, Brooks-Rooney C, Kusel J, Costello S*



#### **PHP145**

The Burden of Evidence in the Pharmaceutical Appraisal Process

*Hamer N, Brooks-Rooney C, Timm B, Leonard S, Costello S*

#### **PHP152**

The Administrative Burden of Patient Access Schemes in the Changing UK Healthcare System: A Follow Up Study

*Haynes S, Timm B, Hamerslag L, Wong G, Costello S*

#### **PRM9**

What Guidance is Available for Budget Impact Analysis?

*Kusel J, Leonard S, Wilson T, Costello S*

---

### **ISPOR 16<sup>th</sup> Annual International Meeting, May 2011, Baltimore, MD, USA**

#### **PRM3**

The Burden of Caregiving: Assessing the Status of Current Clinical Research

*Hamer N, Costello S, Hamerslag L, Haynes S, Roper S*

#### **PHP5**

Incentive-based Interventions – Rewarding Patients for Good Behaviour

*Haynes S, Costello S, Brooks-Rooney C, Hamer N*

#### **PHP7**

Developing Public Health Guidance - What are the Data Gaps? Review of the Gaps in the Evidence Identified by NICE in the UK

*Kusel J, Hamer N, Roper S, Hamerslag L, Costello S*

#### **PHP43**

The Influence of Patient Access Schemes on Appraisal Decisions by NICE in the UK

*Timm B, Kusel J, Hamer N, Brooks-Rooney C, Costello S*

#### **PHP89**

The Implementation of Public Health Guidance: Preference for Clinical over Behavioural Interventions

*Hamerslag L, Kusel J, Haynes S, Brooks-Rooney C, Costello S*

#### **PMS69**

The Use of Mixed Treatment Comparisons in NICE Technology Appraisals

*Brooks-Rooney C, Costello S, Kusel J, Timm B*

---

### **ISPOR 13<sup>th</sup> Annual European Congress, November 2010, Prague, Czech Republic**

#### **NI4**

Do Patient Access Schemes Result in an Acceptable Administrative Burden?

*Haynes S, Costello S, Brooks-Rooney C, Hamer N*

#### **PHP94**

Is it Cost-Effective to Change the Behaviour of Healthcare Professionals?

*Kusel J, Costello S, Haynes S, Brooks-Rooney C, Hamer N, Timm B*

#### **PHP98**

Cost-Effectiveness Methodologies of Strategies that Aim to Change the Behaviour of Healthcare Professionals

*Kusel J, Costello S, Haynes S, Brooks-Rooney C, Hamer N, Timm B*

---

### **ISPOR 15<sup>th</sup> Annual International Meeting, May 2010, Atlanta, GA, USA**

#### **PHP79**

Innovative Pricing Agreements in UK NICE Submissions

*Costello S, Haynes S, Kusel J, Brooks-Rooney C, Hamer N*